In Chinese drug quality audits, non-conformances are addressed through corrective and preventive actions (CAPA). Companies must investigate root causes, implement corrective measures, and document actions taken. Regulatory authorities may conduct follow-up inspections to ensure compliance. Continuous monitoring and staff training are emphasized to prevent recurrence and maintain quality standards.